Mylan Speciality Lp patent expiration

1. Accuneb patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6702997 MYLAN SPECIALITY LP Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma
Dec, 2021

(2 years ago)




Drugs and Companies using ALBUTEROL SULFATE ingredient

Market Authorisation Date: 30 April, 2001

Treatment: Indicated for the relief of bronchospasm in patients 2-12 years of age with asthma (reversible obstructive airway disease)

Dosage: SOLUTION

How can I launch a generic of ACCUNEB before it's drug patent expiration?
More Information on Dosage

ACCUNEB family patents

Family Patents

2. Aerospan Hfa patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5776433 MYLAN SPECIALITY LP Flunisolide aerosol formulations
Jul, 2015

(9 years ago)

US5980867 MYLAN SPECIALITY LP Flunisolide aerosol formulations
Jul, 2018

(6 years ago)




Drug Exclusivity Drug Exclusivity Expiration
M(M-128) Aug 28, 2016

Drugs and Companies using FLUNISOLIDE ingredient

Market Authorisation Date: 27 January, 2006

Treatment: NA

Dosage: AEROSOL, METERED

More Information on Dosage

AEROSPAN HFA family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Astepro patent expiration

ASTEPRO IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8518919 MYLAN SPECIALITY LP Compositions comprising azelastine and methods of use thereof
Nov, 2025

(1 year, 4 months from now)

US9919050 MYLAN SPECIALITY LP Compositions comprising azelastine
Nov, 2025

(1 year, 4 months from now)

US8071073 MYLAN SPECIALITY LP Compositions comprising azelastine and methods of use thereof
Jun, 2028

(3 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Oct 15, 2011
M(M-129) Aug 30, 2016
New Patient Population(NPP) Feb 20, 2018

Drugs and Companies using AZELASTINE HYDROCHLORIDE ingredient

Market Authorisation Date: 15 October, 2008

Treatment: Treatment of allergic rhinitis, including seasonal and perennial allergic rhinitis

Dosage: SPRAY, METERED

How can I launch a generic of ASTEPRO before it's drug patent expiration?
More Information on Dosage

ASTEPRO family patents

Family Patents

4. Duoneb patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6632842 MYLAN SPECIALITY LP Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
Dec, 2021

(2 years ago)




Drugs and Companies using ALBUTEROL SULFATE; IPRATROPIUM BROMIDE ingredient

Market Authorisation Date: 21 March, 2001

Treatment: Treatment of bronchospasm associated with copd in patients requiring more than one broncho dilator

Dosage: SOLUTION

How can I launch a generic of DUONEB before it's drug patent expiration?
More Information on Dosage

DUONEB family patents

Family Patents

5. Dymista patent expiration

DYMISTA's oppositions filed in EPO
DYMISTA IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9901585 MYLAN SPECIALITY LP Combination of azelastine and fluticasone for nasal administration
Jun, 2023

(1 year, 1 month ago)

US9259428 MYLAN SPECIALITY LP Combination of azelastine and fluticasone for nasal administration
Jun, 2023

(1 year, 1 month ago)

US8163723 MYLAN SPECIALITY LP Combination of azelastine and steroids
Aug, 2023

(10 months ago)

US9259428

(Pediatric)

MYLAN SPECIALITY LP Combination of azelastine and fluticasone for nasal administration
Dec, 2023

(7 months ago)

US8163723

(Pediatric)

MYLAN SPECIALITY LP Combination of azelastine and steroids
Feb, 2024

(4 months ago)

US8168620 MYLAN SPECIALITY LP Combination of azelastine and steroids
Feb, 2026

(1 year, 7 months from now)

US8168620

(Pediatric)

MYLAN SPECIALITY LP Combination of azelastine and steroids
Aug, 2026

(2 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) May 01, 2015
New Patient Population(NPP) Feb 20, 2018
Pediatric Exclusivity(PED) Aug 20, 2018

Drugs and Companies using AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 01 May, 2012

Treatment: Treatment of seasonal allergic rhinitis

Dosage: SPRAY, METERED

How can I launch a generic of DYMISTA before it's drug patent expiration?
More Information on Dosage

DYMISTA family patents

Family Patents

6. Edluar patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8512747 MYLAN SPECIALITY LP Pharmaceutical composition for the treatment of acute disorders
Sep, 2019

(4 years ago)

US6761910 MYLAN SPECIALITY LP Pharmaceutical composition for the treatment of acute disorders
Sep, 2019

(4 years ago)

US9597281 MYLAN SPECIALITY LP Pharmaceutical formulations useful in the treatment of insomnia
Apr, 2027

(2 years from now)

US9265720 MYLAN SPECIALITY LP Pharmaceutical formulations useful in the treatment of insomnia
Feb, 2031

(6 years from now)




Drugs and Companies using ZOLPIDEM TARTRATE ingredient

Market Authorisation Date: 13 March, 2009

Treatment: Method of treating insomnia characterized by difficulty with sleep onset

Dosage: TABLET

How can I launch a generic of EDLUAR before it's drug patent expiration?
More Information on Dosage

EDLUAR family patents

Family Patents

7. Elestrin patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7470433 MYLAN SPECIALITY LP Formulations for transdermal or transmucosal application
Aug, 2021

(2 years ago)

US7198801 MYLAN SPECIALITY LP Formulations for transdermal or transmucosal application
Jun, 2022

(2 years ago)




Drugs and Companies using ESTRADIOL ingredient

Market Authorisation Date: 15 December, 2006

Treatment: NA

Dosage: GEL, METERED

More Information on Dosage

ELESTRIN family patents

Family Patents

8. Epipen patent expiration

EPIPEN's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7449012 MYLAN SPECIALITY LP Automatic injector
Sep, 2025

(1 year, 1 month from now)

US8048035 MYLAN SPECIALITY LP Automatic injector with needle cover
Sep, 2025

(1 year, 1 month from now)

US9586010 MYLAN SPECIALITY LP Automatic injector with needle cover
Sep, 2025

(1 year, 1 month from now)

US8870827 MYLAN SPECIALITY LP Automatic injector
Sep, 2025

(1 year, 1 month from now)

US7794432 MYLAN SPECIALITY LP Automatic injector with kickback attenuation
Sep, 2025

(1 year, 1 month from now)




Drugs and Companies using EPINEPHRINE ingredient

Market Authorisation Date: 03 August, 1995

Treatment: NA

Dosage: INJECTABLE

How can I launch a generic of EPIPEN before it's drug patent expiration?
More Information on Dosage

EPIPEN family patents

Family Patents

9. Epipen Jr. patent expiration

EPIPEN JR.'s oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9586010 MYLAN SPECIALITY LP Automatic injector with needle cover
Sep, 2025

(1 year, 1 month from now)

US7449012 MYLAN SPECIALITY LP Automatic injector
Sep, 2025

(1 year, 1 month from now)

US7794432 MYLAN SPECIALITY LP Automatic injector with kickback attenuation
Sep, 2025

(1 year, 1 month from now)

US8048035 MYLAN SPECIALITY LP Automatic injector with needle cover
Sep, 2025

(1 year, 1 month from now)

US8870827 MYLAN SPECIALITY LP Automatic injector
Sep, 2025

(1 year, 1 month from now)




Drugs and Companies using EPINEPHRINE ingredient

Market Authorisation Date: 03 August, 1995

Treatment: NA

Dosage: INJECTABLE

How can I launch a generic of EPIPEN JR. before it's drug patent expiration?
More Information on Dosage

EPIPEN JR. family patents

Family Patents

10. Muse patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5474535 MYLAN SPECIALITY LP Dosage and inserter for treatment of erectile dysfunction
Dec, 2012

(11 years ago)

US5886039 MYLAN SPECIALITY LP Method and composition for treating erectile dysfunction
Mar, 2016

(8 years ago)




Drugs and Companies using ALPROSTADIL ingredient

Market Authorisation Date: 19 November, 1996

Treatment: Treatment of erectile dysfunction

Dosage: SUPPOSITORY

More Information on Dosage

MUSE family patents

Family Patents

11. Sfrowasa patent expiration

SFROWASA IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7645801 MYLAN SPECIALITY LP Reduced irritant enema for treatment of inflammatory bowel disease (IBD)
Jul, 2027

(3 years from now)




Drugs and Companies using MESALAMINE ingredient

Market Authorisation Date: 24 December, 1987

Treatment: NA

Dosage: ENEMA

More Information on Dosage

SFROWASA family patents

Family Patents

12. Tobi patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5508269 MYLAN SPECIALITY LP Aminoglycoside formulation for aerosolization
Oct, 2014

(9 years ago)




Drugs and Companies using TOBRAMYCIN ingredient

Market Authorisation Date: 22 December, 1997

Treatment: Treatment of cystic fibrosis patients with pseudomonas aeruginosa

Dosage: SOLUTION

How can I launch a generic of TOBI before it's drug patent expiration?
More Information on Dosage

TOBI family patents

Family Patents

13. Tobi Podhaler patent expiration

TOBI PODHALER's oppositions filed in EPO
TOBI PODHALER IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8349294 MYLAN SPECIALITY LP Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
May, 2020

(4 years ago)

US7442388 MYLAN SPECIALITY LP Phospholipid-based powders for drug delivery
May, 2020

(4 years ago)

US7097827 MYLAN SPECIALITY LP Devices, compositions and methods for the pulmonary delivery of aerosolized medicaments
Jun, 2021

(3 years ago)

US8715623 MYLAN SPECIALITY LP Pulmonary delivery of aminoglycoside
Dec, 2022

(1 year, 6 months ago)

US7368102 MYLAN SPECIALITY LP Pulmonary delivery of aminoglycosides
Dec, 2022

(1 year, 6 months ago)

US9421166 MYLAN SPECIALITY LP Pulmonary delivery of aminoglycoside
Dec, 2022

(1 year, 6 months ago)

US7516741 MYLAN SPECIALITY LP Aerosolization apparatus with feedback mechanism
Jan, 2024

(6 months ago)

USRE47526 MYLAN SPECIALITY LP Aerosolization apparatus with air inlet shield
Apr, 2024

(3 months ago)

US8069851 MYLAN SPECIALITY LP Aeorosolization apparatus with air inlet shield
Sep, 2024

(2 months from now)

US11484671 MYLAN SPECIALITY LP Aerosolization apparatus with capsule puncture alignment guide
Nov, 2024

(3 months from now)

US8664187 MYLAN SPECIALITY LP Methods of treatment of endobronchial infections
Jun, 2025

(11 months from now)

US7559325 MYLAN SPECIALITY LP Aerosolization apparatus with air inlet shield
Oct, 2025

(1 year, 3 months from now)

US8869794 MYLAN SPECIALITY LP Aerosolization apparatus with capsule puncturing member
Sep, 2028

(4 years from now)

US10207066 MYLAN SPECIALITY LP Aerosolization apparatus with capsule puncture alignment guide
Nov, 2030

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Mar 22, 2016

Drugs and Companies using TOBRAMYCIN ingredient

Market Authorisation Date: 22 March, 2013

Treatment: Treatment of cystic fibrosis patients with pseudomonas aeruginosa

Dosage: POWDER

More Information on Dosage

TOBI PODHALER family patents

Family Patents